Cover Image
市場調查報告書

普拉得威利症候群(PWS):開發中產品分析

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321896
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
普拉得威利症候群(PWS):開發中產品分析 Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 58 Pages
簡介

普拉得威利症候群(PWS)是出生時出現許多身體功能障礙,精神功能障礙,行動障礙的罕見遺傳性疾病。症狀有肌肉張力低落,性荷爾蒙低,持續性的飢餓感等。

本報告提供普拉得威利症候群(PWS)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

普拉得威利症候群(PWS)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Chong Kun Dang Pharmaceutical Corp.
  • Essentialis, Inc.
  • Ferring International Center S.A.
  • LG Life Sciences, Ltd.
  • P2D Bioscience
  • Pfizer Inc.
  • Rhythm Pharmaceuticals

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • beloranib
  • betahistine hydrochloride
  • diazoxide choline CR
  • FE-992097
  • NOX-B11
  • setmelanotide
  • somatropin SR

開發中產品的最新趨勢

產品開發的里程碑

  • 熱門新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8252IDB

Summary

Global Markets Direct's, 'Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016', provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
  • The report reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Prader-Willi Syndrome (PWS) therapeutics and enlists all their major and minor projects
  • The report assesses Prader-Willi Syndrome (PWS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prader-Willi Syndrome (PWS) Overview
  • Therapeutics Development
    • Pipeline Products for Prader-Willi Syndrome (PWS) - Overview
    • Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis
  • Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies
  • Prader-Willi Syndrome (PWS) - Therapeutics under Investigation by Universities/Institutes
  • Prader-Willi Syndrome (PWS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Prader-Willi Syndrome (PWS) - Products under Development by Companies
  • Prader-Willi Syndrome (PWS) - Products under Investigation by Universities/Institutes
  • Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
    • Alize Pharma SAS
    • Essentialis, Inc.
    • Ferring International Center S.A.
    • Helsinn Healthcare S.A.
    • LG Life Science LTD.
  • Prader-Willi Syndrome (PWS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AZP-531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carbetocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazoxide choline CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAL-671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setmelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prader-Willi Syndrome (PWS) - Dormant Projects
  • Prader-Willi Syndrome (PWS) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 05, 2016: Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference
      • Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome
      • Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
      • Sep 25, 2015: Essentialis Presents Results From Clinical Study PC025 Evaluating DCCR in the Treatment of Prader-Willi Syndrome at Annual Meeting of the Foundation for Prader-Willi Research
      • Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome
      • Sep 09, 2015: Essentialis Announces the Dosing of the First Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025
      • Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
      • Mar 26, 2015: Essentialis Presents Results From the First Phase of Clinical Study PC025 Evaluating DCCR in the Treatment of Prader-Willi Syndrome at ACMG Annual Clinical Genetic Meeting
      • Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome
      • Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research
      • Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome
      • Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome
      • Jun 17, 2014: Essentialis Announces the Grant of its First Japanese Patent Which Provides Extensive Protection to DCCR in the Treatment of Prader-Willi Syndrome
      • May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2016
  • Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H2 2016
  • Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H2 2016
  • Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H2 2016
  • Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Healthcare S.A., H2 2016
  • Prader-Willi Syndrome (PWS) - Pipeline by LG Life Science LTD., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2016
  • Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top